Next Article in Journal
Aggressiveness of Grade 4 Gliomas of Adults
Previous Article in Journal
Severe Stenosis of Mitral Bioprosthetic Valve Thrombosis in a Patient with HCV-Related Cirrhosis and Duodenal Variceal Bleeding: The Deadly Triad
 
 
Article

Accrual-Monitoring Practices for Various Disease Trials among AACI Member Cancer Centers

1
Department of Otolaryngology–Head and Neck Surgery, Thomas Jefferson University, Philadelphia, PA 19144, USA
2
Department of Medical Oncology, Philadelphia, Thomas Jefferson University, Philadelphia, PA 19144, USA
3
Sidney Kimmel Cancer Center Protocol Review Committee, Thomas Jefferson University, Philadelphia, PA 19144, USA
*
Author to whom correspondence should be addressed.
Academic Editors: Anna Capasso and Gururaj Arakeri
Clin. Pract. 2022, 12(5), 692-700; https://doi.org/10.3390/clinpract12050072
Received: 22 June 2022 / Revised: 26 August 2022 / Accepted: 30 August 2022 / Published: 31 August 2022
Progress in the management of rare diseases, including rare cancers, is dependent upon clinical trials; however, as many as 32% of rare-disease trials go uncompleted or unpublished due to insufficient accrual. Monitoring practices may differ between institutions. We sought to survey the regulatory standards for various trial types among major U.S. cancer centers. A 10-question survey was designed using Qualtrics assessment software. The survey was sent via email to an internal server of member institutions of the Association of American Cancer Institutes (AACI). Of 103 AACI centers, 31% completed the survey (n = 32). Respondents differed in their definitions of a rare disease, minimum expectations for rare tumor studies, and frequency of accrual monitoring by their institutional Protocol Review and Monitoring Committee. Seventy-three percent of respondents did not close trials based on low accrual. Strategies to optimize accrual included investigator incentives for high accrual and penalties for low accrual in 37% and 13% of respondents, respectively. View Full-Text
Keywords: rare diseases; clinical trials; accrual and monitoring rare diseases; clinical trials; accrual and monitoring
MDPI and ACS Style

Elliott, Z.T.; Goldberg, Z.; Philips, R.; Johnson, J.M.; Kasner, M.T.; Kelly, W.K.; Osipowicz, S.; Dampman, R.; Curry, J.M. Accrual-Monitoring Practices for Various Disease Trials among AACI Member Cancer Centers. Clin. Pract. 2022, 12, 692-700. https://doi.org/10.3390/clinpract12050072

AMA Style

Elliott ZT, Goldberg Z, Philips R, Johnson JM, Kasner MT, Kelly WK, Osipowicz S, Dampman R, Curry JM. Accrual-Monitoring Practices for Various Disease Trials among AACI Member Cancer Centers. Clinics and Practice. 2022; 12(5):692-700. https://doi.org/10.3390/clinpract12050072

Chicago/Turabian Style

Elliott, Zachary T., Zachary Goldberg, Ramez Philips, Jennifer M. Johnson, Margaret T. Kasner, William K. Kelly, Sarah Osipowicz, Rachael Dampman, and Joseph M. Curry. 2022. "Accrual-Monitoring Practices for Various Disease Trials among AACI Member Cancer Centers" Clinics and Practice 12, no. 5: 692-700. https://doi.org/10.3390/clinpract12050072

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop